01—Abstract
Summary
Summary of the 8-K filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.
CVS Health reported third-quarter 2024 results that were sharply weaker on profitability even as top-line revenue grew.
Total revenues rose 6.3% year over year to $95.4 billiona, but GAAP operating income fell 77.5% to $832 million and GAAP diluted EPS dropped to $0.07 from $1.75. Adjusted EPS declined to $1.09 from $2.21, and adjusted operating income fell 42.8% to $2.5 billion. The decline is concentrated in the Health Care Benefits segment, which posted an adjusted operating loss of $924 million and a medical benefit ratio (MBR) of 95.2%, up from 85.7%.
Drivers include elevated utilization, roughly $1.1 billionb of premium deficiency reserves (PDR) tied to anticipated fourth-quarter losses in Medicare and individual exchange lines, higher Medicaid acuity, and the unfavorable impact of lower Medicare Advantage star ratings for 2024. The quarter also included about $1.2 billion of restructuring charges, including a $607 million store impairment for retail pharmacy closures planned for 2025, which further depressed GAAP results. Partially offsetting the weakness, the Health Services and Pharmacy & Consumer Wellness segments grew adjusted operating income by 17.4% and 14.9%, respectively.
Management said the PDR reserves are expected to be substantially released in the fourth quarter of 2024, which would benefit results in that period. Year-to-date operating cash flow was $7.2 billionc, down from $16.1 billion a year earlier, and year-to-date share repurchases were $3.0 billion.
For investors, the central questions are whether the Health Care Benefits utilization pressure is durable, whether the PDR release materializes as guided, and whether the enterprise restructuring delivers its promised cost savings. The filing itself is the furnishing of an earnings press release under Item 2.02, so the figures are management-reported and not audited for this period.
02—Key points
Key Highlights
- Total revenues rose 6.3% to $95.4 billion, driven by Health Care Benefits (+25.5%) and Pharmacy & Consumer Wellness (+12.3%), partly offset by a 5.9% decline in Health Services.
- GAAP diluted EPS fell to $0.07 from $1.75; Adjusted EPS fell to $1.09 from $2.21, reflecting a sharp deterioration in Health Care Benefits.
- Health Care Benefits posted an adjusted operating loss of $924 million versus $1.5 billion of income a year earlier, with MBR rising 950 bps to 95.2%.
- About $1.1 billion of premium deficiency reserves were recorded for anticipated Q4 2024 losses in Medicare and individual exchange lines, expected to be substantially released in Q4 2024.
- Restructuring charges of approximately $1.2 billion, including a $607 million store impairment tied to retail store closures planned for 2025, drove GAAP operating income down 77.5% to $832 million.
- Health Services adjusted operating income rose 17.4% to $2.2 billion and Pharmacy & Consumer Wellness rose 14.9% to $1.6 billion, showing resilience outside the benefits business.
- Year-to-date operating cash flow declined to $7.2 billion from $16.1 billion, while medical membership grew to 27.1 million.
03—Questions
Frequently Asked Questions
Why did CVS's earnings decline so sharply in the third quarter of 2024?
The decline was driven mainly by the Health Care Benefits segment, which faced higher medical utilization, about $1.1 billion of premium deficiency reserves for expected Q4 losses, higher Medicaid acuity after redeterminations resumed, and lower Medicare Advantage star ratings. Restructuring charges of roughly $1.2 billion further reduced GAAP operating income.
What are premium deficiency reserves and will they reverse?
A premium deficiency reserve is recorded when expected costs for a product line exceed expected premium revenue, so the loss is recognized early. CVS stated the roughly $1.1 billion reserve for Medicare and individual exchange lines is expected to be substantially released in Q4 2024, which would boost results in that period, though actual release depends on fourth-quarter performance.
What does the restructuring program involve and what does it cost?
CVS finalized an enterprise-wide plan to streamline operations and cut costs. The Q3 charge of about $1.2 billion includes a $607 million store impairment for retail pharmacy closures planned for 2025, $293 million for corporate workforce optimization and severance, and $269 million for other asset impairments tied to discontinuing non-core assets.
Are the Health Services and Pharmacy segments still growing profitably?
Yes. Health Services adjusted operating income rose 17.4% to $2.2 billion on improved purchasing economics, although revenue fell 5.9% after the loss of a large client. Pharmacy & Consumer Wellness adjusted operating income rose 14.9% to $1.6 billion, driven by higher prescription volume, including vaccinations, and better drug purchasing.
How did the company's cash generation and capital allocation look?
Year-to-date operating cash flow was $7.2 billion, down from $16.1 billion in the prior year, largely due to higher insurance benefits paid and other liability changes. The company repurchased $3.0 billion of common stock and paid $2.5 billion in dividends over the first nine months, while long-term debt rose to about $59.8 billion.
04—Continue